Follow Us
   Twitter   YouTube

What We Do...

To accomplish our mission the Hepatitis Foundation International initiates a wide range of programs that keep us on the go! The common thread in each one is to educate the public, patients, and professionals about the prevention, diagnosis, and treatment of viral hepatitis.

National Nurses Advisory Council on Liver Wellness
and Viral Hepatitis Launched by HFI

One of the greatest untapped resources in the fight against viral hepatitis is “nurses”. A survey of a a number of professional nurses who attended Hepatitis Foundation International’s National Viral hepatitis Summit last November called attention to many gap areas in the identification, diagnosis, treatment and prevention of viral hepatitis. To provide a coordinated effort to address these issues, HFI convened a meeting of nurse practitioners to establish a National Nurses Advisory Council on Liver Wellness and Viral hepatitis (NNAC). The purpose of the Council is to provide nurses with a “voice” to address many of their concerns related to the quality of care provided patients and to promote primary and secondary prevention. The overall goal of the newly developed NNAC is to develop a national plan of action to created a communication network to provide nurses nationwide with information and tools to implement the best practices in patient care, to promote liver wellness and the prevention of viral hepatitis, and to serve as advocates related to issues they have identified.

The Mission of the National Nurse Advisory Council on Liver Wellness and Viral hepatitis is:

  • To improve hepatitis related health outcomes and promote liver wellness through the establishment of education and prevention program at all levels of society, collaborating with both public and private organizations.

Back to top

Training the Trainers:
Changing Risky Behaviors with Unique Motivating Messages

Hepatitis and Substance Abuse Prevention, Quick and Easy Techniques With Proven Success — Motivating individuals to take responsibility for their own health care and to avoid risky behaviors that expose them to AIDS, and hepatitis viruses that lead to serious liver damage is a difficult task. It depends a great deal on having knowledge and understanding of basic functions of the liver, what vital role it plays in their health and well being, and how it can be compromised by drugs, alcohol, environmental pollutants and hepatitis viruses.

Back to top

HFI Assists Task Force On Drug-Resistant Infections

The growing menace of drug resistant infections has led a federal inter-agency task force to develop a plan of action to combat them. Created last year, the Task Force on Anti-microbial Resistance (AR) released a draft copy of its initial action plan in January. This Task Force, co-chaired by the Centers for Disease Control and Prevention and the National Institutes of Health, was assisted by outside experts, including HFI's Chairwoman, Thelma King Thiel. Despite the urgency of the problem, the battle against AR has been inadequate to date. HFI is among the first to pledge itself to this national plan of action against AR. The Task Force's Public Action Plan will address AR in four areas:

Surveillance — The plan envisions efforts to coordinate, integrate and build on existing surveillance activities. Steps will be taken to improve the detection and reporting of AR through training and testing, increased monitoring, and enhanced surveillance in agricultural settings.

Prevention and Control — The goals are: extending the life of anti-microbial drugs; improving testing practices; preventing transmission by improved infection control; preventing emerging AR problems in agriculture; and ensuring that non-federal partners are involved in the process.

Research — A government-wide external review will identify needed AR research. Infrastructure for this research will be augmented. The government will assist basic research for vaccines and treatments and focus on gaps not filled by the pharmaceutical industry.

Product Development — The priorities include insuring that researchers and drug companies are informed about gaps in the arsenal of drugs to fight AR and streamlining the regulatory approval process for new products. The Task Force observed that AR will always be with us. The challenge is to turn this threat into a manageable problem.